Publications for Roopali Sharma

Touro College of Pharmacy (New York)
  • Moy, S., & Sharma, R. (2017). Treatment outcomes in infections caused by "SPICE" (Serratia, Pseudomonas, indole-positive Proteus, Citrobacter, and Enterobacter) organisms: Carbapenem versus noncarbapenem Regimens. Clinical Therapeutics, 39(1), 170-176. doi:10.1016/j.clinthera.2016.11.025

  • Banniettis, N., Sharma, R., Hand, I., Peloquin, C. A., Kohlhoff, S., & Hammerschlag, M. R. (2016). Steady-state pharmacokinetics of oral linezolid suspension in a premature infant with osteomyelitis. Journal of Antimicrobial Chemotherapy, 71(6), 1738-1739. doi:10.1093/jac/dkv507

  • Park, T. E., Yusuff, J., Sharma, R. (2016). Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection. International Journal of STD & AIDS, 27(6), 447-452. doi:10.1177/0956462415585448

  • Sharma, R., Park, T. E., & Moy, S. (2016). Ceftazidime-avibactam: A novel cephalosporin/β-lactamase inhibitor combination for the treatment of resistant gram-negative organisms. Clinical Therapeutics, 38(3), 431-444. doi:10.1016/j.clinthera.2016.01.018

  • Swamy, S., & Sharma, R. (2016). Duration of treatment of gram-negative bacteremia: Are shorter courses of antimicrobial therapy feasible? Infectious Diseases in Clinical Practice, 24(3), 155-160. doi:10.1097/IPC.0000000000000362

  • Moy, S., & Sharma, R. (2015). Treatment outcomes for infections caused by "SPICE" (S–Serratia, P–Pseudomonas aeruginosa, I–Indole positive Proteus, C–Citrobacter, E–Enterobacter) organisms: Carbapenem versus non-carbapenem regimens. Open Forum Infectious Diseases, 2(Suppl. 1), S241. This material can be found here.

  • Park, T. E., Mohamed, A., Kalabalik, J., & Sharma, R. (2015). Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Review of Anti-Infective Therapy, 13(10), 1195-1212. doi:10.1586/14787210.2015.1075393